12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Kotobuki, Shionogi deal

Kotobuki granted Shionogi exclusive, worldwide rights to develop and commercialize cholesterol absorption inhibitor KT6-971. Kotobuki will receive an upfront payment...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >